Q2 2015 & H1 2015 Earnings Update - Report on Argos Therapeutics

NEW YORK, September 16, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Argos Therapeutics, Inc. (NASADQ: ARGS). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/reports?keyword=ARGS  

Highlights from our ARGS Report include:

• Top-line & Bottom-line Review - On August 12, 2015, the biopharmaceutical company, Argos Therapeutics, Inc., announced results for the second quarter and half year 2015 (period ended June 30, 2015). The Company's revenue for the quarter declined to $0.1 million, compared to $0.5 million in the corresponding period a year ago. For the six month, revenue was reported at $0.3 million, as against $1.3 million in the year-ago period. As per the transcript of the second quarter conference call released by Seeking Alpha, VP of Finance at Argos Therapeutics, Lori Harrelson informed that the expected decline in revenue is due to the winding down of activities in the Company's Phase 2b clinical trial of AGS-004, which resulted in decreased reimbursement under its NIH contract. Net loss attributable to Argos shareholders widened to $19.6 million, or $0.95 per share in Q2 2015; compared to a net loss of $12.0 million, or $0.61 per share, for the same period in 2014. For H1 2015, net loss stood at $37.2 million, or $1.84 per share, as against a net loss of 22.8 million, or $1.52 per share for H1 2014.

• Operational Performance - During the quarter, Argos's research & development (R&D) expenses grew to $16.1 million from $10.6 million in Q2 2014. Meanwhile, the same grew to $30.9 million for H1 2015 from $19.0 million in H1 2014. As per the aforementioned transcript, the increase R&D expenses during both periods were primarily due to increased activity in connection with our pivotal Phase 3 clinical trial of AGS-003 and their commercial manufacturing development efforts. General and administrative expense totaled $2.9 million during the quarter as compared to $1.9 million for the same period in 2014. Meanwhile, General and administrative expense for H1 2015 totaled $5.3 million, higher from $3.8 million in H1 2014. The increase in General and administrative expense during both periods was primarily due to increases in personnel cost, including stock-based compensation, outside services including consulting services, and other expenses incurred due to our status as a public company.

• Management's Comments  - On operational front, President and Chief Executive Officer, Jeff Abbey remarked, "We have made important progress this quarter in our ongoing pivotal phase 3 ADAPT trial with AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). He added, "We are pleased with the independent data monitoring committee's (IDMC) recommendation to continue the trial following the first of three planned interim data analyses. We look forward to further IDMC reviews and interim data analyses as the trial advances."

To find out how this influences our rating on Argos Therapeutics, Inc., read the full report in its entirety here: http://www.aciassociation.com/reports?keyword=ARGS

-- 

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.  

NO WARRANTY 

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com